All In Biotech

Drug Trial Radar · NCT06834542

Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors

Single Arm Clinical Study of Autologous Tumor Infiltrating Lymphocyte Injection (GT201) in the Treatment of Advanced Gynecological Tumors

Last checked: Nov 19, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

1

Actual

Start

Nov 1, 2022

Primary completion

Dec 30, 2025

Study completion Dec 30, 2025

Sponsor

Lead sponsor
Grit BiotechnologyIndustry
Sponsor type
Industry
First posted
Feb 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an early exploration clinical study with one arm. The study consists of two stages, namely the dose escalation stage and the dose extension stage:

Conditions

  • Adult Gynecological Tumors

Interventions

  • Autologous tumor infiltrating lymphocyte injection(GT201)Biological

    GT201 treatment for advanced gynecological tumors (advanced cervical cancer)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response RateTime frame: 3 years
  2. Incidence and severity of adcersed events per CTCAE 5.0Time frame: 3 years
  3. Progression-Free SurvivalTime frame: 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Jiaotong University School of Medcine, Renji Hospital Ethica Committee

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.